Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD8359 in Metastatic Prostate Cancer
NCT07529717Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- May 2026
- Primary completion
- Nov 2027
- Modality
- Bispecific Antibodies, T-cell Engagers, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 2, open-label trial of AZD8359 in prostate cancer (PCa) (4 arms), sponsored by AstraZeneca. Primary endpoints: Number of participants with adverse events, adverse events of special interest, and serious adverse events up to 3 years, Number of participants with dose-limiting toxicity at 28 days and 1 more. Started May 2026; status: recruiting.
02
Drugs
AZD8359
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07529717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07529717.